Free for academic non-profit institutions. Other users need a Commercial license
This gene encodes a cytoplasmic protein tyrosine kinase which is involved in calcium-induced regulation of ion channels and activation of the map kinase signaling pathway. The encoded protein may represent an important signaling intermediate between neuropeptide-activated receptors or neurotransmitters that increase calcium flux and the downstream signals that regulate neuronal activity. The encoded protein undergoes rapid tyrosine phosphorylation and activation in response to increases in the intracellular calcium concentration, nicotinic acetylcholine receptor activation, membrane depolarization, or protein kinase C activation. This protein has been shown to bind CRK-associated substrate, nephrocystin, GTPase regulator associated with FAK, and the SH2 domain of GRB2. The encoded protein is a member of the FAK subfamily of protein tyrosine kinases but lacks significant sequence similarity to kinases from other subfamilies. Four transcript variants encoding two different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
PTK2B (Protein Tyrosine Kinase 2 Beta) is a Protein Coding gene. Diseases associated with PTK2B include Osteoporosis and Osteopetrosis. Among its related pathways are Translation Translation regulation by Alpha-1 adrenergic receptors and Sweet Taste Signaling. Gene Ontology (GO) annotations related to this gene include transferase activity, transferring phosphorus-containing groups and protein tyrosine kinase activity. An important paralog of this gene is PTK2.
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0000166 | nucleotide binding | IEA | -- |
GO:0004672 | protein kinase activity | IEA | -- |
GO:0004683 | calmodulin-dependent protein kinase activity | ISS | -- |
GO:0004713 | protein tyrosine kinase activity | TAS | 8939945 |
GO:0004715 | non-membrane spanning protein tyrosine kinase activity | TAS,IDA | 7544443 |
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0005623 | cell | IEA | -- |
GO:0005634 | nucleus | IEA,IDA | 19880522 |
GO:0005737 | cytoplasm | TAS | 7499242 |
GO:0005829 | cytosol | TAS | -- |
GO:0005856 | cytoskeleton | IEA | -- |
SuperPathway | Contained pathways | ||
---|---|---|---|
1 | ERK Signaling |
ERK Signaling
.61
Rho Family GTPases
.61
MAPK Signaling
.58
|
Molecular Mechanisms of Cancer
.51
ILK Signaling
.49
|
2 | Integrin Pathway |
Integrin Pathway
.67
GnRH Signaling
.56
|
UPA-UPAR Pathway
.56
Transendothelial Migration of Leukocytes
.38
|
3 | Development Angiotensin activation of ERK |
Development ACM2 and ACM4 activation of ERK
.73
Development Angiotensin activation of ERK
.73
|
Development Angiotensin signaling via PYK2
.68
Development G-Proteins mediated regulation MARK-ERK signaling
.65
|
4 | CCR5 Pathway in Macrophages |
CCR5 Pathway in Macrophages
.52
Chemokine Signaling
.33
|
|
5 | Development Endothelin-1/EDNRA signaling |
Development Endothelin-1/EDNRA signaling
.41
Development Endothelin-1/EDNRA transactivation of EGFR
.41
|
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0000165 | MAPK cascade | IEA | -- |
GO:0000302 | response to reactive oxygen species | IEA | -- |
GO:0001525 | angiogenesis | IBA | 21873635 |
GO:0001556 | oocyte maturation | IEA | -- |
GO:0001666 | response to hypoxia | IEA | -- |
Name | Status | Disease Links | Group | Role | Mechanism of Action | Clinical Trials |
---|---|---|---|---|---|---|
Leflunomide | Approved, Investigational | Pharma | Target, antagonist | AHR agonist,immunosuppressive agent | 91 | |
Baricitinib | Approved, Investigational | Pharma | Target, inhibitor | 0 | ||
fostamatinib | Approved, Investigational | Pharma | Target, inhibitor | Kinase Inhibitors | 0 | |
4-{[4-{[(1R,2R)-2-(dimethylamino)cyclopentyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}-N-methylbenzenesulfonamide | Experimental | Pharma | Target | 0 | ||
Genistein | Investigational | Pharma | Activator, Potentiation, Agonist, Target | AR agonist, EGFR kinase inhibitor. Also estrogen and PPARgamma ligand | 59 |
Name | Synonyms | Role | CAS Number | PubChem IDs | PubMed IDs | |
---|---|---|---|---|---|---|
ADP |
|
Agonist, Full agonist, Partial agonist, Gating inhibitor, Antagonist | 58-64-0 | |||
LysoPA(0:0/16:0) |
|
|
||||
LysoPA(0:0/18:0) |
|
|
|
|||
LysoPA(0:0/18:1(9Z)) |
|
|
||||
LysoPA(0:0/18:2(9Z,12Z)) |
|
|
|
Compound | Action | Cas Number |
---|---|---|
FAK Inhibitor 14 | 4506-66-5 | |
PF-00562271 | FAK/Pyk2 inhibitor,potent and ATP-competitive | 939791-38-5 |
PF-431396 | Pyk2 and FAK inhibitor | 717906-29-1 |
PF-562271 | ATP-competitive FAK inhibitor, reversible | 717907-75-0 |
PF-562271 HCl | FAK/Pyk2 inhibitor | |
TAE226 (NVP-TAE226) | FAK inhibitor,potent and ATP-competitive | 761437-28-9 |
Y 11 | 1086639-59-9 |
ExUns: | 1 | ^ | 2 | ^ | 3a | · | 3b | · | 3c | ^ | 4 | ^ | 5 | ^ | 6a | · | 6b | ^ | 7a | · | 7b | ^ | 8 | ^ | 9 | ^ | 10 | ^ | 11 | ^ | 12a | · | 12b | · | 12c | ^ | 13 | ^ | 14a | · | 14b | ^ | 15 | ^ | 16 | ^ | 17 | ^ | 18 | ^ | 19 | ^ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SP1: | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||
SP2: | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||
SP3: | ||||||||||||||||||||||||||||||||||||||||||||||||||||
SP4: | - | |||||||||||||||||||||||||||||||||||||||||||||||||||
SP5: | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||
SP6: | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||
SP7: | ||||||||||||||||||||||||||||||||||||||||||||||||||||
SP8: | ||||||||||||||||||||||||||||||||||||||||||||||||||||
SP9: | - | |||||||||||||||||||||||||||||||||||||||||||||||||||
SP10: | - | - |
ExUns: | 20 | ^ | 21 | ^ | 22 | ^ | 23 | ^ | 24 | ^ | 25 | ^ | 26 | ^ | 27 | ^ | 28 | ^ | 29a | · | 29b | ^ | 30 | ^ | 31 | ^ | 32 | ^ | 33 | ^ | 34 | ^ | 35 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SP1: | |||||||||||||||||||||||||||||||||
SP2: | |||||||||||||||||||||||||||||||||
SP3: | - | ||||||||||||||||||||||||||||||||
SP4: | |||||||||||||||||||||||||||||||||
SP5: | |||||||||||||||||||||||||||||||||
SP6: | |||||||||||||||||||||||||||||||||
SP7: | |||||||||||||||||||||||||||||||||
SP8: | |||||||||||||||||||||||||||||||||
SP9: | |||||||||||||||||||||||||||||||||
SP10: |
This gene was present in the common ancestor of animals.
Organism | Taxonomy | Gene | Similarity | Type | Details |
---|---|---|---|---|---|
Chimpanzee (Pan troglodytes) |
Mammalia | PTK2B 30 31 |
|
OneToOne | |
Oppossum (Monodelphis domestica) |
Mammalia | PTK2B 31 |
|
OneToOne | |
Dog (Canis familiaris) |
Mammalia | PTK2B 30 31 |
|
OneToOne | |
Cow (Bos Taurus) |
Mammalia | PTK2B 30 31 |
|
OneToOne | |
Mouse (Mus musculus) |
Mammalia | Ptk2b 30 17 31 |
|
OneToOne | |
Rat (Rattus norvegicus) |
Mammalia | Ptk2b 30 |
|
||
Platypus (Ornithorhynchus anatinus) |
Mammalia | PTK2B 31 |
|
OneToOne | |
Chicken (Gallus gallus) |
Aves | PTK2B 30 31 |
|
OneToOne | |
Lizard (Anolis carolinensis) |
Reptilia | PTK2B 31 |
|
OneToOne | |
Tropical Clawed Frog (Silurana tropicalis) |
Amphibia | ptk2b 30 |
|
||
Zebrafish (Danio rerio) |
Actinopterygii | ptk2ba 31 |
|
OneToMany | |
ptk2bb 31 |
|
OneToMany | |||
-- 30 |
|
||||
Fruit Fly (Drosophila melanogaster) |
Insecta | Fak56D 31 32 |
|
OneToMany | |
Worm (Caenorhabditis elegans) |
Secernentea | kin-23 32 |
|
|
|
kin-32 31 32 |
|
OneToMany | |||
Sea Squirt (Ciona savignyi) |
Ascidiacea | CSA.5720 31 |
|
OneToMany |
SNP ID | Clinical significance and condition | Chr 08 pos | Variation | AA Info | Type |
---|---|---|---|---|---|
747284 | Likely Benign: not provided | 27,420,047(+) | G/A | SYNONYMOUS_VARIANT | |
773403 | Benign: not provided | 27,422,366(+) | G/A | SYNONYMOUS_VARIANT | |
775261 | Likely Benign: not provided | 27,433,522(+) | C/G | MISSENSE_VARIANT | |
776301 | Benign: not provided | 27,435,789(+) | C/T | SYNONYMOUS_VARIANT | |
786557 | Benign: not provided | 27,440,228(+) | A/G | INTRON_VARIANT |
Variant ID | Type | Subtype | PubMed ID |
---|---|---|---|
dgv1390e214 | CNV | gain | 21293372 |
esv2092173 | CNV | deletion | 18987734 |
esv2430348 | CNV | insertion | 19546169 |
esv2673904 | CNV | deletion | 23128226 |
esv2676555 | CNV | deletion | 23128226 |
esv3381982 | CNV | duplication | 20981092 |
esv3441155 | CNV | insertion | 20981092 |
esv3616717 | CNV | gain | 21293372 |
esv3616719 | CNV | loss | 21293372 |
esv3616721 | CNV | gain | 21293372 |
esv3616722 | CNV | loss | 21293372 |
esv3616723 | CNV | loss | 21293372 |
nsv1020582 | CNV | gain | 25217958 |
nsv1149289 | CNV | deletion | 26484159 |
nsv471719 | CNV | loss | 16327809 |
Disorder | Aliases | PubMed IDs |
---|---|---|
osteoporosis |
|
|
osteopetrosis |
|
|
transient cerebral ischemia |
|
|
lung cancer |
|
|
leukemia, chronic myeloid |
|